{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:45:36Z","timestamp":1792896336120,"version":"4.5.0"},"reference-count":49,"publisher":"Massachusetts Medical Society","issue":"2","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lexicon"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2021,1,14]]},"DOI":"10.1056\/nejmoa2030186","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T21:06:30Z","timestamp":1605560790000},"page":"129-139","source":"Crossref","is-referenced-by-count":1082,"title":["Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease"],"prefix":"10.1056","volume":"384","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"first","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Szarek","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4596-2791","authenticated-orcid":false,"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia B.","family":"Lewis","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Riddle","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie P.","family":"Dwyer","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Scirica","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford J.","family":"Bailey","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"D\u00edaz","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0508-0954","authenticated-orcid":false,"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Udell","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Lapuerta","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-2941","authenticated-orcid":false,"given":"P. Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"From Brigham and Women\u2019s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.","volume":"304","author":"Bhatt DL","year":"2010","unstructured":"Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304:1350-1357.20805624","journal-title":"JAMA"},{"key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis.","volume":"297","author":"Steg PG","year":"2007","unstructured":"Steg PG, Bhatt DL, Wilson PWF, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-1206.17374814","journal-title":"JAMA"},{"key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.","volume":"295","author":"Bhatt DL","year":"2006","unstructured":"Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-189.16403930","journal-title":"JAMA"},{"key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry.","volume":"132","author":"Cavender MA","year":"2015","unstructured":"Cavender MA, Steg PG, Smith SC Jr, et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 2015;132:923-931.26152709","journal-title":"Circulation"},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.","volume":"369","author":"Scirica BM","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326.23992601","journal-title":"N Engl J Med"},{"key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(15)00044-3","article-title":"Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials.","volume":"3","author":"Udell JA","year":"2015","unstructured":"Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015;3:356-366.25791290","journal-title":"Lancet Diabetes Endocrinol"},{"key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamacardio.2016.3030","article-title":"Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial.","volume":"1","author":"Scirica BM","year":"2016","unstructured":"Scirica BM, Bhatt DL, Braunwald E, et al. Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol 2016;1:989-998.27681000","journal-title":"JAMA Cardiol"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cmet.2019.10.008","article-title":"The DAPA-HF trial: a momentous victory in the war against heart failure.","volume":"30","author":"Bhatt DL","year":"2019","unstructured":"Bhatt DL, Verma S, Braunwald E. The DAPA-HF trial: a momentous victory in the war against heart failure. Cell Metab 2019;30:847-849.31693879","journal-title":"Cell Metab"},{"key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/CIRCULATIONAHA.119.041181","article-title":"More CREDENCE for SGLT2 inhibition.","volume":"140","author":"Verma S","year":"2019","unstructured":"Verma S, Bhatt DL. More CREDENCE for SGLT2 inhibition. Circulation 2019;140:1448-1450.31181959","journal-title":"Circulation"},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cmet.2018.11.010","article-title":"Can we DECLARE a victory against cardio-renal disease in diabetes?","volume":"28","author":"Connelly KA","year":"2018","unstructured":"Connelly KA, Bhatt DL, Verma S. Can we DECLARE a victory against cardio-renal disease in diabetes? Cell Metab 2018;28:813-815.30517896","journal-title":"Cell Metab"},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128.26378978","journal-title":"N Engl J Med"},{"key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657.28605608","journal-title":"N Engl J Med"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-2306.30990260","journal-title":"N Engl J Med"},{"key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-357.30415602","journal-title":"N Engl J Med"},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.","volume":"130","author":"Scirica BM","year":"2014","unstructured":"Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014;130:1579-1588.25189213","journal-title":"Circulation"},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus.","volume":"139","author":"Kato ET","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019;139:2528-2536.30882238","journal-title":"Circulation"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"393","author":"Zelniker TA","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31-39.30424892","journal-title":"Lancet"},{"key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1016\/j.jacc.2018.08.2202","article-title":"Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration labeling.","volume":"72","author":"Vaduganathan M","year":"2018","unstructured":"Vaduganathan M, Sathiyakumar V, Singh A, et al. Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration labeling. J Am Coll Cardiol 2018;72:3370-3372.30409566","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink HJL","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436-1446.32970396","journal-title":"N Engl J Med"},{"key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes.","volume":"383","author":"Cannon CP","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020;383:1425-1435.32966714","journal-title":"N Engl J Med"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray JJV","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008.31535829","journal-title":"N Engl J Med"},{"key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413-1424.32865377","journal-title":"N Engl J Med"},{"key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2337\/dc14-1850","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.","volume":"38","author":"Udell JA","year":"2015","unstructured":"Udell JA, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705.25552421","journal-title":"Diabetes Care"},{"key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes.","volume":"377","author":"Garg SK","year":"2017","unstructured":"Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017;377:2337-2348.28899222","journal-title":"N Engl J Med"},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","DOI":"10.1111\/dom.14127","article-title":"Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2.","author":"Rodbard HW","year":"2020","unstructured":"Rodbard HW, Giaccari A, Lajara R, et al. Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2. Diabetes Obes Metab 2020 July 3 (Epub ahead of print).32618383","journal-title":"Diabetes Obes Metab"},{"key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2337\/dc14-2806","article-title":"Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes.","volume":"38","author":"Sands AT","year":"2015","unstructured":"Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015;38:1181-1188.26049551","journal-title":"Diabetes Care"},{"key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"e1235","DOI":"10.1210\/clinem\/dgz258","article-title":"Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption.","volume":"105","author":"Powell DR","year":"2020","unstructured":"Powell DR, Zambrowicz B, Morrow L, et al. Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption. J Clin Endocrinol Metab 2020;105(4):e1235-e1249.31837264","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study.","volume":"41","author":"Buse JB","year":"2018","unstructured":"Buse JB, Garg SK, Rosenstock J, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. Diabetes Care 2018;41:1970-1980.29937430","journal-title":"Diabetes Care"},{"key":"e_1_3_5_30_2","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study.","volume":"41","author":"Danne T","year":"2018","unstructured":"Danne T, Cariou B, Banks P, et al. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study. Diabetes Care 2018;41:1981-1990.29937431","journal-title":"Diabetes Care"},{"key":"e_1_3_5_31_2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jacc.2020.05.041","article-title":"The consequences of the COVID-19 pandemic on non-COVID-19 clinical trials.","volume":"76","author":"Bagiella E","year":"2020","unstructured":"Bagiella E, Bhatt DL, Gaudino M. The consequences of the COVID-19 pandemic on non-COVID-19 clinical trials. J Am Coll Cardiol 2020;76:342-345.32470514","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_5_32_2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10985-019-09462-4","article-title":"Modeling marginal features in studies of recurrent events in the presence of a terminal event.","volume":"25","author":"Andersen PK","year":"2019","unstructured":"Andersen PK, Angst J, Ravn H. Modeling marginal features in studies of recurrent events in the presence of a terminal event. Lifetime Data Anal 2019;25:681-695.30697652","journal-title":"Lifetime Data Anal"},{"key":"e_1_3_5_33_2","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/sim.4780131709","article-title":"Standardized rates of recurrent outcomes.","volume":"13","author":"Stukel TA","year":"1994","unstructured":"Stukel TA, Glynn RJ, Fisher ES, Sharp SM, Lu-Yao G, Wennberg JE. Standardized rates of recurrent outcomes. Stat Med 1994;13:1781-1791.7997711","journal-title":"Stat Med"},{"key":"e_1_3_5_34_2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cmet.2019.08.015","article-title":"SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus.","volume":"30","author":"Hess DA","year":"2019","unstructured":"Hess DA, Terenzi DC, Trac JZ, et al. SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus. Cell Metab 2019;30:609-613.31477497","journal-title":"Cell Metab"},{"key":"e_1_3_5_35_2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbrc.2020.01.015","article-title":"The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.","volume":"524","author":"Chowdhury B","year":"2020","unstructured":"Chowdhury B, Luu AZ, Luu VZ, et al. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochem Biophys Res Commun 2020;524:50-56.31980166","journal-title":"Biochem Biophys Res Commun"},{"key":"e_1_3_5_36_2","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1139\/cjpp-2018-0359","article-title":"Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications.","volume":"96","author":"Kumar N","year":"2018","unstructured":"Kumar N, Garg A, Bhatt DL, et al. Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications. Can J Physiol Pharmacol 2018;96:1184-1187.30265814","journal-title":"Can J Physiol Pharmacol"},{"key":"e_1_3_5_37_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jacbts.2018.01.010","article-title":"Canagliflozin improves the recovery of blood flow in an experimental model of severe limb ischemia.","volume":"3","author":"Sherman SE","year":"2018","unstructured":"Sherman SE, Bell GI, Teoh H, et al. Canagliflozin improves the recovery of blood flow in an experimental model of severe limb ischemia. JACC Basic Transl Sci 2018;3:327-329.30062217","journal-title":"JACC Basic Transl Sci"},{"key":"e_1_3_5_38_2","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dci19-0074","article-title":"SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action.","volume":"43","author":"Packer M","year":"2020","unstructured":"Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care 2020;43:508-511.32079684","journal-title":"Diabetes Care"},{"key":"e_1_3_5_39_2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2337\/dc19-1410","article-title":"Reinterpreting cardiorenal protection of renal sodium-glucose cotransporter 2 inhibitors via cellular life history programming.","volume":"43","author":"Avogaro A","year":"2020","unstructured":"Avogaro A, Fadini GP, Del Prato S. Reinterpreting cardiorenal protection of renal sodium-glucose cotransporter 2 inhibitors via cellular life history programming. Diabetes Care 2020;43:501-507.31843950","journal-title":"Diabetes Care"},{"issue":"3","key":"e_1_3_5_40_2","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.2337\/dc18-1959","article-title":"Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME Trial.","volume":"42","author":"Verma S","year":"2019","unstructured":"Verma S, Mazer CD, Bhatt DL, et al. Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2019;42(3):e42-e44.30674547","journal-title":"Diabetes Care"},{"key":"e_1_3_5_41_2","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial.","volume":"140","author":"Verma S","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation 2019;140:1693-1702.31434508","journal-title":"Circulation"},{"key":"e_1_3_5_42_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/ndt\/gfz294","article-title":"The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial.","volume":"35","author":"Opingari E","year":"2020","unstructured":"Opingari E, Verma S, Connelly KA, et al. The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. Nephrol Dial Transplant 2020;35:895-897.32159783","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_3_5_43_2","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jacc.2018.07.061","article-title":"Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk.","volume":"72","author":"Seidelmann SB","year":"2018","unstructured":"Seidelmann SB, Feofanova E, Yu B, et al. Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk. J Am Coll Cardiol 2018;72:1763-1773.30286918","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_5_44_2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41569-020-00439-7","article-title":"The COVID-19 pandemic: a catalyst to improve clinical trials.","volume":"17","author":"Gaba P","year":"2020","unstructured":"Gaba P, Bhatt DL. The COVID-19 pandemic: a catalyst to improve clinical trials. Nat Rev Cardiol 2020;17:673-675.32873977","journal-title":"Nat Rev Cardiol"},{"key":"e_1_3_5_45_2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.jacc.2020.07.051","article-title":"Effects of the COVID pandemic on active non-COVID clinical trials.","volume":"76","author":"Gaudino M","year":"2020","unstructured":"Gaudino M, Arvind V, Hameed I, et al. Effects of the COVID pandemic on active non-COVID clinical trials. J Am Coll Cardiol 2020;76:1605-1606.32745501","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"e_1_3_5_46_2","doi-asserted-by":"crossref","first-page":"e018274","DOI":"10.1161\/JAHA.120.018274","article-title":"The landscape of cardiovascular clinical trials in the United States initiated before and during COVID-19.","volume":"9","author":"Selvaraj S","year":"2020","unstructured":"Selvaraj S, Greene SJ, Khatana SAM, Nathan AS, Solomon SD, Bhatt DL. The landscape of cardiovascular clinical trials in the United States initiated before and during COVID-19. J Am Heart Assoc 2020;9(18):e018274-e018274.32713281","journal-title":"J Am Heart Assoc"},{"key":"e_1_3_5_47_2","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease.","volume":"363","author":"Bhatt DL","year":"2010","unstructured":"Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-1917.20925534","journal-title":"N Engl J Med"},{"key":"e_1_3_5_48_2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jacc.2015.11.027","article-title":"Investigator-reported bleeding versus post hoc adjudication of bleeding: lessons from the CHAMPION PHOENIX Trial.","volume":"67","author":"Jatene T","year":"2016","unstructured":"Jatene T, Harrington RA, Stone GW, et al. Investigator-reported bleeding versus post hoc adjudication of bleeding: lessons from the CHAMPION PHOENIX Trial. J Am Coll Cardiol 2016;67:596-598.26846956","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"e_1_3_5_49_2","doi-asserted-by":"crossref","first-page":"e006720","DOI":"10.1161\/CIRCHEARTFAILURE.119.006720","article-title":"Comparison of outcome adjudication by investigators and by a central end point committee in heart failure trials: experience of the SHIFT heart failure study.","volume":"13","author":"Tyl B","year":"2020","unstructured":"Tyl B, Lopez Sendon J, Borer JS, et al. Comparison of outcome adjudication by investigators and by a central end point committee in heart failure trials: experience of the SHIFT heart failure study. Circ Heart Fail 2020;13(7):e006720-e006720.32580655","journal-title":"Circ Heart Fail"},{"key":"e_1_3_5_50_2","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/S0140-6736(18)31184-X","article-title":"Endpoints in diabetes cardiovascular outcome trials.","volume":"391","author":"Patel T","year":"2018","unstructured":"Patel T, Tesfaldet B, Chowdhury I, et al. Endpoints in diabetes cardiovascular outcome trials. Lancet 2018;391:2412-2412.29916379","journal-title":"Lancet"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2030186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T20:34:32Z","timestamp":1711485272000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2030186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1,14]]}},"alternative-id":["10.1056\/NEJMoa2030186"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2030186","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739048448.793580922","asserted-by":"object"}]},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]}}}